Evidence map›Paper›PMID 32066473›Full record

ArticleAIDS research and therapy2020

Epidemiologic and viral predictors of antiretroviral drug resistance among persons living with HIV in a large treatment program in Nigeria.

Ernest Ekong, Nicaise Ndembi, Prosper Okonkwo, Patrick Dakum, John Idoko, Bolanle Banigbe, James Okuma, Patricia Agaba, William Blattner, Clement Adebamowo and 1 more

Abstract read
In one paragraph

Article in AIDS research and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ernest EkongDepartment of Prevention, Care and Treatment, Institute of Human Virology-Nigeria (IHVN), Federal Capital Territory, Plot 252, Herbert Macaulay Way, Central Business District, Abuja, Nigeria. ernestekong@ihvnigeria.org.
Nicaise NdembiDepartment of Prevention, Care and Treatment, Institute of Human Virology-Nigeria (IHVN), Federal Capital Territory, Plot 252, Herbert Macaulay Way, Central Business District, Abuja, Nigeria. nndembi@ihvnigeria.org.ORCID 0000-0002-9498-3428
Prosper OkonkwoAIDS Prevention Initiative, Abuja, Nigeria.
Patrick DakumDepartment of Prevention, Care and Treatment, Institute of Human Virology-Nigeria (IHVN), Federal Capital Territory, Plot 252, Herbert Macaulay Way, Central Business District, Abuja, Nigeria.
John IdokoJos University Teaching Hospital, Jos, Nigeria.
Bolanle BanigbeAIDS Prevention Initiative, Abuja, Nigeria.
James OkumaDepartment of Prevention, Care and Treatment, Institute of Human Virology-Nigeria (IHVN), Federal Capital Territory, Plot 252, Herbert Macaulay Way, Central Business District, Abuja, Nigeria.
Patricia AgabaJos University Teaching Hospital, Jos, Nigeria.
William BlattnerInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.
Clement AdebamowoInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.
Manhattan CharuratInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.

Funding

PROTEOLYTIC REGULATION OF PICORNAVIRAL MORPHOGENESISR01AI017331 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI PALMENBERG, ANN C. · 1985 to 2013
$3.7M
NIAID NIH HHS R01 AI017331
6 · The paper itself

Abstract

backgroundExpanded access to combination antiretroviral therapy (cART) throughout sub-Saharan Africa over the last decade has remarkably improved the prognosis of persons living with HIV (PLWH). However, some PLWH experience virologic rebound after a period of viral suppression, usually followed by selection of drug resistant virus. Determining factors associated with drug resistance can inform patient management and healthcare policies, particularly in resource-limited settings where drug resistance testing is not routine.

methodsA case-control study was conducted using data captured from an electronic medical record in a large treatment program in Nigeria. Cases PLWH receiving cART who developed acquired drug resistance (ADR) and controls were those without ADR between 2004 and 2011. Each case was matched to up to 2 controls by sex, age, and education. Logistic regression was used estimate odds ratios (ORs) and 95% confidence intervals (CIs) for factors associated with ADR.

resultsWe evaluated 159 cases with ADR and 299 controls without ADR. In a multivariate model, factors associated with ADR included older age (OR = 2.35 [age 30-40 years 95% CI 1.29, 4.27], age 41 + years OR = 2.31 [95% CI 1.11, 4.84], compared to age 17-30), higher education level (secondary OR 2.14 [95% CI 1.1.11-4.13]), compared to primary and tertiary), non-adherence to care (OR = 2.48 [95% CI 1.50-4.00]), longer treatment duration (OR = 1.80 [95% CI 1.37-2.35]), lower CD4 count((OR = 0.95 [95% CI 0.95-0.97]) and higher viral load (OR = 1.97 [95% CI 1.44-2.54]).

conclusionsUnderstanding these predictors may guide programs in developing interventions to identify patients at risk of developing ADR and implementing prevention strategies.

Indexed as

Drug Resistance, ViralAdolescentAdultAnti-HIV AgentsCase-Control StudiesCD4 Lymphocyte CountElectronic Health RecordsFemaleHealth ResourcesHIV-1HIV InfectionsHumansMaleNigeriaTreatment FailureViral LoadAnti-HIV AgentsAcquired drug resistanceAntiretroviral therapyHIV drug resistance testingLow Middle Income Countries (LMICs)PredictorsResource-limited settings

Identifiers

PMID32066473
PMCPMC7027291

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.